A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Advanced solid tumors

- Histological or cytological confirmation of a malignancy that is advanced (metastatic
and/or unresectable) with measureable disease as defined by Response Evaluation
Criteria In Solid Tumors (RECIST) v1.1

- At least 1 lesion accessible for biopsy in addition to the target lesion

- Participants must have received, and then progressed or been intolerant to, at least 1
standard treatment regimen

- Eastern Cooperative Oncology Group (ECOG) performance status ≤2

Exclusion Criteria:

- Participants with active central nervous system (CNS) metastases, untreated CNS
metastases, or with the CNS as the only site of disease are excluded (controlled brain
metastases will be allowed to enroll)

- Participants with carcinomatous meningitis

- Prior malignancy active within the previous 2 years except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast

- Active, known, or suspected autoimmune disease

- Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply